CLAIMS

1. A composition for topical treatment, comprising:

a) rapamycin as active ingredient;

b) vehicle, comprising:

- monolaurin, for example as glyceryl monolaurate; and
- monomyristin, for example as glyceryl monomyristate; and

c) water as a solvent.

2. A composition according to claim 1, wherein the rapamycin is present in the amount of 0.5 - 5% wt.

3. A composition according to claim 1, wherein the rapamycin is present in the amount of approximately 0.5% wt.

4. A composition according to claim 1, wherein the rapamycin is present in the amount of approximately 1.0 % wt.

5. A composition according to claim 1, wherein the rapamycin is present in the amount of approximately 5.0% wt.

6. A composition according to any one of the preceding claims, for treating angiofibromas.

7. A composition according to any one of the preceding claims, for treating facial angiofibromas.

8. A composition according to any one of the preceding claims, for treating cutaneous vascular lesions.

9. A composition according to any one of the preceding claims, for treating port wine stains.

10. A composition according to any one of the preceding claims, for treating port wine stains after laser treatment thereof.

11. A composition according to any one of the preceding claims, wherein the monolaurin comprises one or more of a monolaurate (eg glycerol monolaurate).

12. A composition according to any one of the preceding claims, wherein the monolaurin is present in the amount of approximately, 7 - 28% wt or approximately 5% - 10% wt, or approximately 7% wt.

13. A composition according to any one of the preceding claims, wherein the monomyristin comprises one or more of a monomyristate, eg glyceryl monomyristate.

14. A composition according to any one of the preceding claims, wherein the monomyristin, eg glyceryl monomyristate, is present in the amount of approximately 7%-28% wt or approximately 15%-25% wt, or approximately 21% wt.

15. A composition according to any one of the preceding claims, comprising:

a) 5% - 9% wt Monolaurin + 19% – 23% wt Monomyristin; or

b) 12% - 16% wt Monolaurin + 12 - 16% wt Monomyristin.

16. A composition according to any one of the preceding claims, comprising:

a) about 7% wt Monolaurin + about 21% wt Monomyristin; or

b) about 14% wt Monolaurin + about 14% wt Monomyristin.

17. A composition according to claim 15 or 16, wherein the rapamycin is present in an amount of about 1% wt.

18. A composition according to any one of the preceding claims, comprising a water retainer.

19. A composition according to claim 18, wherein the water retainer comprises polyoxyethylene stearate.

20. A composition according to any one of the preceding claims, comprising a softener.

21. A composition according to claim 20, wherein the softener comprises one or more of propylene glycol , petrolatum, lanolin, mineral oil, glycerin, lecithin and sorbitol.

22. A composition according to any one of the preceding claims, comprising a buffer.

23. A composition according to claim 22, wherein the buffer comprises one or more of citric acid anhydrous, sodium bicarbonate and triethanolamine.

24. A composition according to any one of the preceding claims, comprising a sequestrant.

25. A composition according to claim 24, wherein the sequestrant comprises one or more of disodium edetate, citric acid and tetrasodium EDTA.

26. A composition according to any one of the preceding claims, comprising hydroxide for pH adjustment.

27. A composition according to any one of the preceding claims, comprising preservative.

28. A composition according to claim 27, wherein the preservative comprises one or more of potassium sorbate, diazolidinyl urea, phenoxyethanol and sodium hydroxymethylglycinate .

29. A composition according to any one of the preceding claims, wherein the water is present in the amount of 58% - 72% wt.

30. A composition according to claim 1, comprising:

a) 0.5 – 5% wt rapamycin;
b) vehicle comprising:
    - 7-28% wt monolaurin; and
    - 7-28% wt monomyristin; and
c) water as a solvent.

31. A composition according to claim 1, comprising 0.5 – 5% wt rapamycin, 5% - 9% wt Monolaurin and 19% - 23% wt Monomyristin.

32. A composition according to claim 31, comprising 0.5 – 5% wt rapamycin, 7% wt Monolaurin and 21% wt Monomyristin.

33. A composition according to claim 31, comprising 1% wt rapamycin, 7% wt Monolaurin and 21% wt Monomyristin.

34. A composition according to claim 1, comprising 0.5 – 5% wt rapamycin, 12% - 16% wt Monolaurin and 12% – 16% wt Monomyristin.

35. A composition according to claim 34, comprising 0.5 – 5% wt rapamycin, 14% wt Monolaurin and 14% wt Monomyristin.

36. A composition according to claim 35, comprising 1% wt rapamycin, 14% wt Monolaurin and 14% wt Monomyristin.

37. A composition according to claim 1, comprising 0.5 – 5% wt rapamycin, 17.5% (±2%) wt Monolaurin and 10.5% (±2%) wt Monomyristin.

38. A composition according to claim 1, comprising 0.5 – 5% wt rapamycin, 17.5% wt Monolaurin and 10.5% wt Monomyristin.

39. A composition according to claim 39, comprising 1% wt rapamycin, 17.5% wt Monolaurin and 10.5% wt Monomyristin.

40. A composition according to claim 1, comprising 1% wt rapamycin, 21% wt Monolaurin and 7% wt Monomyristin.

41. A composition according to any one of claims 31-40, wherein the Monolaurin is glyceryl monolaurate and the Monomyristin is glyceryl monomyristate.

42. A composition according to any one of claims 31-41, formulated to be suitable for treating angiofibromas, cutaneous vascular lesions or port wine stains in humans.

43. A composition according to claim 1, comprising:

a) 0.5 – 5% wt rapamycin;
b) vehicle comprising:
    - 10-18% wt monolaurin; and
    - 10-18% wt monomyristin; and
c) water as a solvent.

44. Use of:

a) rapamycin as active ingredient;

b) vehicle, comprising:

- monolaurin, for example as glyceryl monolaurate; and
- monomyristin, for example as glyceryl monomyristate; and

c) water as a solvent;

in the manufacture of a composition according to any one of the preceding claims, for topical treatment of one or more of the following conditions:

- angiofibromas;
- cutaneous vascular lesions; and
- port wine stains.